1. Home
  2. SRG vs XBIT Comparison

SRG vs XBIT Comparison

Compare SRG & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seritage Growth Properties

SRG

Seritage Growth Properties

HOLD

Current Price

$1.71

Market Cap

102.5M

Sector

Real Estate

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

SELL

Current Price

$2.16

Market Cap

66.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SRG
XBIT
Founded
2015
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Pharmaceuticals and Biotechnology
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
102.5M
66.8M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
SRG
XBIT
Price
$1.71
$2.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 167.7K
26.6K
Earning Date
11-13-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.90
N/A
EPS
★ N/A
N/A
Revenue
★ $18,204,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$30.47
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3.30
N/A
52 Week Low
$1.57
$2.09
52 Week High
$4.38
$3.44

Technical Indicators

Market Signals
Indicator
SRG
XBIT
Relative Strength Index (RSI) 32.95 42.36
Support Level N/A $2.14
Resistance Level $2.08 $2.48
Average True Range (ATR) 0.08 0.03
MACD -0.00 0.00
Stochastic Oscillator 29.41 33.33

Price Performance

Historical Comparison
SRG
XBIT

About SRG Seritage Growth Properties

Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: